Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;34(2):e13762.
doi: 10.1111/ctr.13762. Epub 2020 Jan 8.

Donor History of Malignancy: A Limited Risk for Heart Transplant Recipients

Affiliations

Donor History of Malignancy: A Limited Risk for Heart Transplant Recipients

Sarah E Rudasill et al. Clin Transplant. .

Abstract

Organ donor contraindications are frequently reassessed for impact on recipient outcomes in attempt to meet demand for transplantation. This study retrospectively analyzed the United Network for Organ Sharing (UNOS) registry for adult heart transplants from 1987 to September 2016 to characterize the impact of donor malignancy history in heart transplantation. Kaplan-Meier estimates illustrated 10-year survival. Propensity score matching was utilized for 1:1 matching of donors with and without history of malignancy, and Cox proportional hazards and logistic regressions were used to analyze the matched population. Of 38 781 heart transplants, 622 (1.6%) had a donor history of malignancy. Cox regressions demonstrated that donor malignancy predicted increased 10-year mortality (HR = 1.16 [1.01-1.33]), but this difference did not persist when conditioned upon 1 year post-transplant survival (log-rank = 0.643). Cox regressions of the propensity score-matched population (455 pairs) found no association between donor malignancy and 10-year mortality (HR = 1.02 [0.84-1.24]). Older age and higher rates of hypertension were observed in donors with a history of malignancy whose recipients died within the first year post-transplant. Therefore, increased recipient mortality is likely due to donor characteristics beyond malignancy, creating the potential for expanded donor selection.

Keywords: donor selection; heart transplantation; malignancy; mortality.

Similar articles

See all similar articles

References

REFERENCES

    1. Zhang S, Yuan J, Li W, Ye Q. Organ transplantation from donors (cadaveric or living) with a history of malignancy: review of the literature. Transplant Rev. 2014;28(4):169-175.
    1. Ong L, Esmailian F, Conte AH. Pro: the benefits of utilizing expanded-criteria donors for orthotopic heart transplantation. J Cardiothorac Vasc Anesth. 2014;28(6):1686-1687.
    1. Buell JF, Trofe J, Hanaway MJ, et al. Transmission of donor cancer into cardiothoracic transplant recipients. Surgery. 2001;130(4):660-668.
    1. Watson CJE, Roberts R, Wright KA, et al. How safe is it to transplant organs from deceased donors with primary intracranial malignancy? An analysis of UK registry data: intracranial malignancy in UK organ donors. Am J Transplant. 2010;10(6):1437-1444.
    1. Nalesnik MA, Woodle ES, DiMaio JM, et al. Donor-transmitted malignancies in organ transplantation: assessment of clinical risk: donor malignancy transmission risk assessment. Am J Transplant. 2011;11(6):1140-1147.

LinkOut - more resources

Feedback